Neoprenessa (Perindopril Arginine)

Perindopril arginine, the active ingredient in Neoprenessa, is an ACE inhibitor presented as an oral tablet for oral use. It treats hypertension, heart failure and left ventricular dysfunction in adult patients. GNH USA supplies Neoprenessa as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neoprenessa, an ACE inhibitor, is used to manage conditions related to the renin‑angiotensin system.

- Hypertension: lowers systemic blood pressure by promoting vasodilation. - Heart failure: improves cardiac output and reduces symptoms of fluid overload. - Left ventricular dysfunction: helps preserve ventricular function and slows disease progression.

Neoprenessa may cause a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Cough: dry, persistent throat irritation. - Dizziness: especially upon standing. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Hypotension: low blood pressure, particularly after the first dose. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or airway. - Severe hypotension: marked drop in blood pressure causing faintness. - Renal impairment: worsening kidney function. - Hyperkalemia: elevated blood potassium levels. - Neutropenia: reduced white blood cell count. - Elevated liver enzymes: signs of hepatic stress.

When prescribing Neoprenessa, clinicians should consider several precautionary measures.

- Monitor blood pressure: check regularly, especially after dose changes. - Assess renal function: evaluate serum creatinine and eGFR before and during therapy. - Check electrolytes: monitor potassium and sodium levels. - Avoid in patients with history of angioedema: contraindicated due to risk of recurrence. - Use caution in pregnancy: limited data; risk‑benefit assessment required. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Neoprenessa can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal dysfunction. - Potassium‑sparing diuretics or potassium supplements: risk of hyperkalemia. - Lithium: elevated lithium concentrations, possible toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Thiazide diuretics: can enhance hypotensive response. - Other ACE inhibitors or ARBs: additive risk of angioedema and renal impairment.